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Abstract: Background: The purpose of this study was to identify the needs, preferences, and values
of patients with differentiated thyroid cancer (DTC) and the physicians treating patients with DTC
regarding two different treatment decisions, namely: the extent of primary surgery (low-risk patients)
and the tyrosine kinase inhibitor (TKI) treatment (high-risk patients). Methods: A qualitative study
was conducted. There were two physician focus groups discussing the extent of primary surgery.
One included endocrinologists (n = 4) and surgeons (n = 5), and the other included nuclear medicine
physicians (n = 3) treating patients with low-risk DTC. The physicians focus group discussing waiting
or starting TKIs included endocrinologists (n = 2) and oncologists (n = 5) treating patients with
advanced radioactive iodide (RAI) refractory DTC. Moreover, one patient focus group per treatment
decision took place. In total 13 patients and 19 physicians participated. Interviews were audio-taped,
fully transcribed verbatim, and analyzed. Results: Several themes were identified. Patients, but
not physicians, mentioned the importance of a strong doctor–patient relationship. Patients in both
treatment decision groups wanted to receive more detailed information, whereas physicians preferred
providing more general information. Patients in the TKI decision group focused on palliative care,
whereas physicians focused more on the effect and benefit of TKIs. Conclusions: Considering the
identified themes in DTC, based on the patients’ needs, preferences, and values, enables us to improve
doctor–patient communication and to develop decision support tools.
Keywords: differentiated thyroid cancer; information needs and preferences; focus group interview
1. Introduction
Most patients with low-risk differentiated thyroid cancer (DTC) have an excellent
long-term prognosis [1–4]. Up to 30% of DTC patients develop recurrent disease and/or
distant metastases. Patients with distant metastases have a five-years survival rate of
approximately 50%, which is worse in those with advanced radioactive iodide (RAI)
refractory DTC [5,6]. Therefore, considering the relatively high survival rates for both low-
risk and high-risk DTC survivors, maintaining long-term quality of life (QOL) is important.
Recently, clinical practice shifted towards more individualized approaches, and pa-
tients are involved in trade-offs between the harms and benefits of different approaches [7].
For patients with low-risk DTC and patients with RAI refractory DTC, the optimal treat-
ment is debated, as insufficient evidence is available regarding the harms and benefits of
treatments in relation to the oncological outcome. As such, some low-risk DTC patients
might undergo overtreatment, thus negatively affecting QOL. The American Thyroid As-
sociation (ATA) guidelines suggest considering patient preferences, as for some low-risk
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patients, thyroid lobectomy (TL) alone may be a sufficient initial treatment [8,9]. Similarly,
for asymptomatic or mildly symptomatic RAI refractory DTC patients, premature starting
of tyrosine kinase inhibitors (TKIs) may expose patients to side-effects and worsening QOL.
The recent European Thyroid Association (ETA) guidelines stated that the decision to start
TKIs should include patient-related medical factors and patient preferences with respect to
treatment goals and values, as well as the acceptance of adverse effects [10]. However, a
recommendation on how to shape the communication process is lacking.
Doctor–patient communication could be improved to consider the patients’ perspec-
tive by using shared decision making (SDM). Accordingly, physicians provide patients
with information on existing options and consider patients’ needs in order to enable a
personalized treatment choice [11]. In this process, important life goals are involved, and
these should be explored together with the patient [12–15]. In practice, however, talking
about values is difficult, and values are discussed in a minority of decision-making con-
sultations [11]. Moreover, exploring values is complicated by different perspectives of
physicians and patients [16].
To facilitate SDM in doctor–patient communication, it is important to determine the
patients’ needs. Decision-support tools, such as decision aids and values clarification
exercises, exist to inform patients and help them explore their values [17,18]. These tools
can be applied in clinical practice. These instruments are not yet available for all patients
with DTC. For developing such tools, knowledge about patients’ and physicians’ needs
is required. Previous studies have explored the patients’ needs in patients with papillary
microcarcinoma (PMC) [19–23] and in patients with larger low-risk DTC (>1 cm) requiring
treatment [24–30]. However, particularly the differences between patients’ and physicians’
needs have not previously been investigated.
To reduce miscommunication between patients and their physicians, we aimed to
identify the needs of DTC patients in two different treatment decision groups in preference-
sensitive decision making, as stated in the ATA and ETA guidelines [9,10]: (1) the extent of
primary surgery, including the need for subsequent ablation of thyroid remnants with RAI
in patients with low-risk DTC (>1 cm), and (2) starting TKIs in patients with advanced RAI
refractory DTC. Our aim was to, on the one hand, address the differences and similarities
between the two treatment decision-making groups (regarding low-risk and high-risk
patients), and on the other hand, between perspectives of physicians and patients for both
decisions. In addition to previous studies, more attention was given to values commu-
nication, given the difficulty in exploring values and to help physicians to discriminate
between their own and patients’ values.
2. Materials and Methods
2.1. Study Design
We performed a qualitative study using semi-structured focus group interviews. The
aim of the interviews was to identify in-depth needs, preferences, and values of DTC
patients in two different treatment decision groups and in physicians treating DTC patients.
This study is part of the COMBO study (COMmunication Booster, NCT03905369), aiming
to develop, evaluate, and implement decision-support tools for DTC patients. Twelve
hospitals (six academic and six non-academic) in the Netherlands participated. The Dutch
patient association “Schildklier Organisatie Nederland (SON)” was also involved. The
Medical Ethical Committee (CMO) of the region Arnhem–Nijmegen approved the study
protocol (MEC-2018-4521). The study is in agreement with the COREQ checklist [31].
2.2. Setting
In the Netherlands, DTC patients undergo treatment in both academic (high- and
low-risk patients) and non-academic hospitals (mainly low-risk patients) involving mul-
tidisciplinary teams of specialists. Long-term follow-up is generally carried out by en-
docrinologists. Patients with advanced RAI refractory disease requiring TKI treatment are
followed-up by oncologists.
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2.3. Participants
2.3.1. Patients
Two treatment decision-making groups were involved, namely: (1) patients with
low-risk DTC according to the ATA criteria [9] who had surgery, and (2) patients with
advanced RAI refractory DTC who started or considered TKIs. The inclusion criteria for the
low-risk group were being diagnosed with DTC, having been treated with surgery within
one year, and being capable of understanding their treatment trajectory as judged by their
physician. Inclusion criteria for the advanced disease group were patients who started
or considered TKIs within one year and were capable of understanding their treatment
trajectory as judged by their physician. Six academic hospitals with expertise in DTC
treatment throughout the Netherlands, as well as the Dutch patient association SON,
selected patients for participation in the interviews. After physicians asked their patients
to participate in the interviews, participants were approached by the researcher (A.K.)
by telephone. Participation was voluntary. All participants provided written informed
consent alongside answers to some demographic questions.
In total, two patient focus groups were organized. One focus group included low-risk
DTC patients (n = 6) discussing thyroid lobectomy or total thyroidectomy, including the
need for the subsequent ablation of thyroid remnants with RAI. The other focus group
included patients with advanced disease (n = 7), discussing the watchful waiting approach
or starting with TKIs decision. The patient focus group interviews took place in the
main investigating center (Radboud University Medical Center). The interviewee had no
treatment relationship with the participants.
2.3.2. Physicians
Physicians (endocrinologists, surgeons, nuclear medicine physicians, and oncologists)
from the above-mentioned expertise centers with extensive expertise on the treatment of
patients with DTC were approached by the researcher (A.K.) by email. All physicians
provided verbal informed consent and answered several questions regarding their clinical
experience. In total, three physician focus groups were organized. To discuss the thyroid
lobectomy or total thyroidectomy decision, two focus groups were organized, as follows:
one included endocrinologists (n = 4) and surgeons (n = 5), and one included nuclear
medicine physicians (n = 3) treating patients with low-risk DTC. To discuss the decision
between watchful waiting or starting with TKIs, another focus group was held, including
endocrinologists (n = 2) and oncologists (n = 5) treating patients with advanced RAI
refractory DTC.
2.4. Data Collection
An expert panel developed an interview guide (Table A1). For both patients and
physicians, the interview guide contained three sections, open-ended questions, and
optional questions to elaborate each topic. The three sections referred to the diagnostic,
treatment, and evaluation phases of DTC care. The interviewer (A.K., first author, female,
MD endocrinology, PhD student, trained in interviewing techniques by a qualitative
research expert) started by explaining the process of the interview. Next, open-ended
questions, not provided in advance, were asked concerning the information given by
the physician during the consultation in the specific treatment phase. The open-ended
questions, focused on needs, preferences, and values; communication with the health care
provider; strong and weak points of the received health care; and points to improve the
current health care. Finally, patients were invited to give their opinion about the content
to be included in a decision-support tool. The focus group interviews were conducted
between May and December 2019. All of the focus group interviews lasted between 26
and 94 min and were audio-taped. One additional observer attended each focus group
and field notes were made during the focus group interviews (R.N.-M. or P.O.). A pilot for
the interview was performed with the first and fourth author (female, senior researcher,
experience with qualitative research). Patients did not receive questions in advance and
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were not informed about the use of the framework to analyse the data using the Picker
domains [32,33].
2.5. Analysis
First, all five focus group interviews were transcribed verbatim and qualitatively
analyzed using ATLAS.ti, 8.4.15 [34]. Two researchers (A.K. and a second coder; female,
experienced coder) independently analyzed all of the transcripts. The perspectives of
patients and physicians and the two different treatment decisions were analyzed separately.
The eight-dimension Picker domains were used as a basis for our analyses (Table A2) [32].
Expressed needs, preferences, and values were categorized into one of the eight Picker
domains, particularly involvement in decisions and respect for preferences, coordination
and integration of care, clear information, and communication and emotional support.
All interviews were open coded independently by both researchers. Open coding allows
for an exploration of the ideas and meaning that were contained in the raw data. Once
codes were created using open coding, they were analyzed using the axial coding process.
This analysis enabled researchers to identify connections between the codes [35]. For axial
coding, two concept coding trees were made, one for the surgery decision and one for the
TKI decision. Both researchers could add, remove, or move the codes of the coding tree.
The codes were compared and discussed until a consensus was reached. Thereafter, the
codes were categorized into similar themes and subthemes within one of the domains. We
aimed to fit all themes into the Picker domains, and a new domain was proposed if the
codes would not fit.
3. Results
All of the invited patients and physicians agreed to participate. The patient and physi-
cian characteristics are displayed in Table 1. Sixteen themes and sixty-three subthemes
were categorized for low-risk DTC patients and their respective physicians. Fifteen themes
and thirty-eight subthemes were categorized for patients with advanced DTC and their
respective physicians. The themes and subthemes fitted within four of the eight Picker
domains (Table A2) [32]; one additional domain occurred, namely values (Tables 2–5 and
Figure 1). Table 2 shows the qualitative results for the surgery decision regarding “thyroid
lobectomy or total thyroidectomy” and Table 3 shows several quotes fitted to the corre-
sponding themes for the decision regarding “thyroid lobectomy or total thyroidectomy”.
Table 4 shows the qualitative results for the decision “to wait or start with TKIs”, and
Table 5 shows several quotes fitted to the corresponding themes for the decision “to wait
or start with TKIs”. The identified domains were as follows.
Table 1. Characteristics of participating patients and physicians.




Age, mean (range), y 57 (31–84)
Caucasian 13 (100)
Married/living together 13 (100)
Educational level:
High school or less 2 (16)




Thyroid lobectomy 3 (50)
Total thyroidectomy 3 (50)
Average time from surgery (mean), m 10.5
Complication rate 1 (17)
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Table 1. Cont.
Characteristics of Patients (n = 13) Number n(%)
TKIs 7 (54)
Not started 4 (57)
Started 3 (43)
Average time from progressive advanced disease (mean), m 6.9
Site of distant metastases
* Lung 6 (60)
* Bone 3 (30)
* Other 1 (10)














y: years, m: months; * site of distant metastases
Table 2. Qualitative results for the surgery decision regarding “thyroid lobectomy or total thyroidectomy”. Expressed
needs, preferences, and values of patients and of physicians treating patients with DTC.
Information Needs for Surgery Decision Making






Personalized care regarding patient values
• Deliberation
• Phone number of the oncology nurse for
support
Doctor–patient relationship







Time to accept the
diagnosis
Patients and physicians: Physicians listen to the
patient, take the patient seriously, and incorporate
the patient’s wishes into the treatment plan. In
addition, patients should be enabled through
enough time and attention given to the patient.
Patients: Patients need a doctor who takes care
and is available most of the time. Integrity and
mutual respect are necessary for a good
doctor–patient relation.
Physicians: Physicians should be available to
answer questions. Integrity and mutual respect are
necessary for a good doctor–patient relationship.
Patients and physicians: After hearing the
diagnosis, most patients need time to accept the





Clarity about healthcare process
• Follow-up







• Way of informing 1
Multidisciplinary team
Patients and physicians: The healthcare path
should make clear what to expect. This means all
steps in follow-up should be made clear. Patients
want to receive information about the healthcare
process on paper or digitally.
Patients and physicians: Patients need to know a
person from the multidisciplinary team who can
answer questions and address health-related
issues. The contact-person should be regularly
available. A tumor board, where physicians can
discuss difficult cases with other healthcare
providers, is important.
Patients: When confronted with illness, patients
seek professional help and advice from their
doctors, and also rely on support from family
members, peers, and fellow patients.
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Table 2. Cont.
Information Needs for Surgery Decision Making













• Thyroid cancer type
• Clear, neutral, and stepwise way
• Diagnosis being told by physician
Information about prognosis
• Nothing about prognosis
• Survival
• Treatment opportunity
• No difference in treatment outcome





• SDM with physician
• Format of explanation 2









• Risk of wait and see
• Psychological pressure after decision
• Consequence of surgery
• Recurrence
Information about medication
• Thyroid hormone substitution
• Additional supplements
• Pregnancy




• Quality of life Information about recovery
after treatment
Information about recovery after treatment
• Possible (negative) effects associated with
each treatment




- Low calcium level
- Fluctuations in thyroid function




• Thyroid cancer type





































Patients: Patients need clear, honest, and complete
information about the diagnosis. Physicians need
to tell every aspect of the diagnosis. Information
on the internet should be of good quality.
Physicians: Patients need short and general
information about the diagnosis. If not, there are
concerns about the amount of information that will
be forgotten.
Patients and physicians: Information about the
prognosis needs to be honest. To talk about
treatment opportunities and outcomes is
important. Especially when there is no difference
in treatment outcomes.
Patients: Clear and detailed information about
different treatment options is important in SDM.
With clear information, patients can deliberate
which option fits them best.
Physicians: To talk about all treatment options is
important in SDM. With clear but short
information, patients are able to deliberate which
option fits them best.
Patients and physicians: Information about the
risks and complications during and after treatment
is important in order to make a considered
decision. The amount and consequences of
complications in daily life are essential in SDM.
Patients: Before patients can make a decision, it is
important to have clear and extensive information
about the medication. What are risks and benefits
of this medication. In addition, the impact on
quality of life is an important part of information
about medication.
Physicians: Before patients can make a decision, it
is important to have complete information about
the medication. Especially about the difficulties of
medication adjustment. In addition, the impact of
quality of life is an important part of information
about medication.
Patients: The possible effects after treatment are
important. Patients specifically want to know what
changes will take place in daily life.
Physicians: Physicians mention that information
about recovery is most important to patients.
4. Emotional
support




Patients: To offer psychological care to every
patient is important. There should be the option to
involve family and friends, for example the option
to bring relatives to hospital appointments.
Reassure patients through clear communication
and the possibility of discussing with other
healthcare providers.
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Table 2. Cont.
Information Needs for Surgery Decision Making
Domain Theme Description of Corresponding Items
Patients Physicians
5. Values






































Patients and physicians: Values are about “what
matters to me”. Values are an important part of
health care decisions. Strengthening and clarifying
patients’ values and preferences in the consultation
is important. Values deliberation is a core step in
the consultation, where the values of physicians
and patients come together to reach a treatment
decision
SDM—shared decision making; 1 To inform patients by paper or digitally/e-mail; 2 Treatment options have to be told in a detailed way.
Table 3. Quotes of patients and physicians corresponding to some of the themes for the surgery decision regarding “thyroid
lobectomy or total thyroidectomy”.
Domain Theme Quotes Patients Quotes Physicians
1. Involvement in decisions and
respect for preferences
Time for processing the
diagnosis
“It is important that you have
time for processing the diagnosis
and that you can think about the
treatment options.”
“The diagnosis of thyroid cancer can
cause anxiety and uncertainty about the
future. Therefore, it is important to give
patients time to process the diagnosis
and make the right decision.”
2. Coordination and integration
of care Multidisciplinary team
“An important part of the
decision making was the
involvement of a tumor
board.”“An oncology nurse is
important for practical issues.”
“When we talk about a patient in our
tumor board, it is possible to discuss the
different treatment options and to
decide if a patient is suitable for shared
decision making.”“We have an oncology
nurse who takes excellent care of our
patients. Patients feel reassured by






“I only remembered that it was
treatable.”“It took a year to adjust
on thyroid medication, it is
necessary to receive information
about this process in advance.”
“I think it is important to tell patients
about their type of cancer and that there
are excellent treatment options with a
very good prognosis.”“It is important to
say something about the adjustment of
thyroid medication and the possibility





“I wavered for a very long time, I
was afraid to make the wrong
treatment decision. When I
discussed this with my physician,
she reassured me and helped me
with my decision.”
-
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Table 4. Qualitative results for the advanced disease decision regarding “wait or start with TKIs”. Expressed information
on the needs, preferences, and values of patients with and of physicians treating patients with DTC.
Information Needs for TKI Decision Making









• Phone number of the
oncology nurse for support
Doctor–patient relationship





• Phone number of the
oncology nurse for support
Doctor–patient relationship
Patients and physicians: Healthcare providers
listen to the patient, take the patient seriously,
and incorporate the patient’s wishes into the
treatment plan. In addition, patients should be
enabled so that there is enough time and
attention for the patient.
Patients: Patients need a doctor who takes care
and is available most of the time. Integrity and
mutual respect are necessary for a good
doctor–patient relationship.
Physicians: Physicians should be available to
answer questions from patients. Integrity and
mutual respect are necessary for a good
doctor–patient relationship.
Patients: After hearing the diagnosis, most
patients need time to accept the diagnosis and














• Way of informing 1
Multidisciplinary team
Patients and physicians: The healthcare path
should make clear what to expect. This means
all steps in follow-up should be made clear.
Patients want to receive information about the
healthcare process on paper or digitally.
Patients and physicians: Patients need to know
a person from the multidisciplinary team to
answer questions and address health-related
issues. The contact-person should be regularly
available. In addition, involving oncology
nurses might result in saving time during the
consult with the doctor, and their involvement
is described as a more personal contact. A
tumor board, where physicians can discuss
difficult cases with other healthcare providers.
Patients: When confronted with illness,
patients seek professional help and advice
from their doctors, and also rely on support
from family members, peers and fellow
patients.
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Table 4. Cont.
Information Needs for TKI Decision Making




























• When to provide
information
• When to start with
medication
• TKIs




effects associated with each
treatment






• Beneft of treatment
• Palliation





• SDM with physician
• Possibility to stop with
TKIs









• When to provide
information
• When to start with
medication
• TKIs
• Sources of information 3
Patients: Patients need clear, honest, and
complete information about the diagnosis.
Physicians need to discuss every aspect of the
diagnosis. Information on the internet should
be of a good quality.
Physicians: Patients need short and general
information about the diagnosis. If such
information is not given, physicians raise
concerns about the amount of information that
will be forgotten.
Patients: Information about the prognosis
needs to be honest. After all, it is a palliative
treatment. Talking about treatment
opportunities and outcomes is important.
Physicians: Information about the prognosis
needs to be honest. Physicians want to focus
on the benefits of treatment, but after all, it is a
palliatve treatment. To talk about treatment
opprtunities and outcomes is important.
Patients: Clear and detailed information about
different treatment options is important in
SDM. With clear information patients can
deliberate which option fits best.
Physicians: To talk about all treatment options
is important in SDM. With clear, but short
information, patients are able to deliberate
which option fits best.
Patients: Before patients are able to decide, it is
important to have clear and extensive
information about the medication. What are
the risks and benefits of this medication. In
addition, the impact on quality of life is an
important part of the information about
medication.
Physicians: Before patients are able to decide,
it is important to have complete information
about the medication. Especially about the side
effects. In addition, the impact on quality of
life is an important part of information about
medication.
Patients: The possible effects after treatment
are important. Patients especially want to















Patients: To offer psychological care to every
patient is important. There should be the
option to involve family and friends, for
example the option to bring relatives to
hospital appointments. Reassure patients by
clear communication and the possibility of
discussing with other healthcare providers.
Physicians: Reassure patients by clear
communication and the possibility of
discussing with other healthcare providers.
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Table 4. Cont.
Information Needs for TKI Decision Making

































Patients and physicians: Values are about
“what matters to me”. Values are an important
part of health care decisions. Strengthening
and clarifying patients’ values and preferences
in the consultation is important. Values
deliberation is a core step in the consultation,
where values of physicians and patients come
together to reach a treatment decision.
SDM—shared decision making; 1 To inform patients by paper or digitally/e-mail; 2 Visually inform patients about survival and recurrence;
3 Different sources of information were the pharmacy, package leaflet of the medicine, and the internet.
Table 5. Quotes of patients and physicians corresponding to some of the themes for the advanced disease decision regarding
“wait or start with TKIs”.




Time for processing the diagnosis
“The fact that you switch from an
endocrinologist to an oncologist with a
waiting room full of patients with cancer
was a real change for me.”
2. Coordination and
integration of care Multidisciplinary team
“A case manager can help, advise, and
reassure when there are problems.”
“We discuss all patients in our
tumor board and decide if






“You know that it is not a curative
treatment and that there will be a moment
when the medication is not longer
working or that you have to stop because
of the side effects.”
“Information about the side effects was
clear and detailed.” “What are the side
effects and what can you expect?”
“It is important to inform patients
about the possible benefit, but also
that it is not a curative treatment.”
“I especially talk about the side




support for emotional problems
“Family means everything, my
granddaughter is always aware that I
cannot do everything. They give so
much love.”
“Patients fear death, so your role
as a physician who supports and
reassures is important.”
5. Values Regarding functioning in daily life
“Quality of life is the most important
value in many different aspects of life.
Maintaining quality of life is important for
being able to participate in sport and
work, but especially for experiencing
family events.”
“What I think is important, some
patients are still working and that
is also quality of life. Patients just
want to keep doing social things,
work, to go on a holiday.”
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Figure 1. Quotes expressed by patients with DTC and by physicians treating patients with DTC for each Picker domain.
3.1. Involvement in Decisions and Respect for Preferences
The importance of a good doctor–patient relationship was most often mentioned
by patients with advanced RAI refractory DTC. Patients indicated the importance of
discussing the treatment steps with family and friends, and listening to patients’ needs and
preferences. They indicated needing a doctor who takes care and is available most of the
time. Integrity and mutual respect were necessary for a good doctor–patient relationship.
For patients treated with surgery, it was important to be involved in their treatment process
and to discuss the options with their physician. The patients in both treatment decision
groups needed time to cope with the diagnosis and its consequences. Physicians in both
treatment decision groups mentioned that patient involvement in the treatment process
was important. The difference between patients and physicians in this domain was the
importance of a good doctor–patient relationship. This theme was rarely mentioned
by physicians.
3.2. Coordination and Integration of Care
Themes mentioned by patients and physicians for both treatment decisions were the
involvement of a multidisciplinary team and information process. It was important to have
a contact person for questions and problems. Patients and physicians for both decisions
mentioned that they considered an oncology nurse as the most suitable multidisciplinary
team member. A tumor board should be available to discuss difficult cases with other
healthcare providers. For both patients and physicians, paper and digital ways of informing
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were considered equally important, and adequate ways to inform patients. In this domain
there were no differences between patients and physicians.
3.3. Clear Information and Communication
Patients in both decision groups needed clear, honest, and complete information. They
also wanted to receive detailed information. The two important themes for patients in the
surgery decision group were general information about DTC and treatment options. For
patients in the TKI decision group, general information about advanced RAI refractory
DTC and medication was important. In both groups, patients were not at all or only
slightly satisfied with the amount of information received. They wanted to receive more
information. Patients in both groups felt they were not involved in decision making,
“there was nothing to choose”. Important themes for physicians discussing the surgery
decision also involved general information about DTC and treatment options. Physicians
mentioned most often “giving information about the prognosis”, especially if patients were
considered to benefit from treatment with TKIs. The main difference in this domain was the
detailed information patients wanted to receive, whereas physicians wanted to give more
general and short information. In the TKI treatment decision group, physicians wanted
to give information about the benefit of therapy, whereas patients were more focused on
palliative care.
3.4. Emotional Support, Empathy and Respect
Patients mentioned the importance of offering psychological care. In both decision
groups, emotional support and the involvement of family was important, as well as
reassurance by health care providers. In both groups, patients felt reassured by their
physician, they also felt that there was sufficient psychological support. Only physicians in
the TKI decision group mentioned reassurance by health care providers. The vast majority
of involved physicians did not mention emotional support or psychological care, which
was the main difference between patients and physicians in this domain. Although few
physicians did not mention it often, they apparently succeeded in reassuring the patients.
3.5. Values
Values were an important part of health care decisions, “what matters to me”. For
patients who started or considered TKIs, the values mentioned most often involved func-
tioning in daily life, for example, maintaining QOL and family milestones. In the surgery de-
cision group, values regarding medical outcomes involved recovery and physical changes
after treatment. In addition, the value “I need surgery, there is something in my body
that does not belong there” was often mentioned. Physicians in the TKI decision group
believed that values about daily life were important. Physicians in the surgery decision
group mentioned medical values most often. The main difference was that patients wanted
to discuss values more.
4. Discussion
This qualitative study investigated the perspectives of patients with low-risk (>1 cm)
DTC and advanced tumors, regarding the extent of surgery or starting TKIs. We studied
the differences between physician and patient perspectives, as well as the differences and
similarities between the aspects involved in these two decisions. The main themes emerging
from both patient and physician interviews were the involvement of a multidisciplinary
team and a way of being informed, general information on DTC and treatment options,
reassurance by health care providers, medical values, and values regarding functioning in
daily life. The main differences in perspective between patients and physicians were that
only patients mentioned the importance of a good doctor–patient relationship, patients
desired detailed information about their diagnosis, patients focused on palliative treatment
whereas physicians focused on the benefit of therapy, and only patients mentioned the
need for psychological care and emotional support. These differences provide valuable
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information on the perspective of patients with DTC and physicians that can be used when
designing decision aid instruments. These differences are elaborated below.
Regarding the doctor–patient relationship, patients in both treatment decision groups
appreciated a good doctor–patient relationship, whereas physicians did not mention
this often. Pitt et al. also showed that patients with low-risk DTC (>1 cm) wished for
a strong patient–surgeon relationship, in line with the findings in patients with other
malignancies [24]. This was particularly important for patients with DTC, who remained in
follow-up and required medical guidance and support for many years, even after remission.
Regarding the desire to receive detailed information, patients from both decision
groups wanted to receive more detailed information about DTC, treatment options, and
aftercare, whereas physicians from both decisions groups preferred providing more general
and short information. We hypothesize that this difference arises from the fact that physi-
cians are limited with respect to the available consultation time and have concerns about
how much of the information is remembered. However, ensuring that the information is
individualized and patients are involved in the treatment process was a strong preference
of our participants. This preference is corroborated by studies focusing on needs in DTC
survivors after primary treatment. Such studies show that survivors usually receive infor-
mation related to their diagnosis, prognosis, and primary treatment; however, information
on long-term effects, recurrence, and aftercare is scarce [25–28,30]. Likewise, a systematic
review of Hyun et al. showed that cancer survivors in general perceive many unmet needs,
and these needs extend to aftercare [29]. Previous studies among other cancer types also
showed the importance of providing patients with disease specific information about cure,
spread of disease, and side effects. There are some possible explanations for this need for
information: (1) it can increase trust in the caring physician and reduce possible feelings of
uncertainty and doubt, and (2) it might be used as a coping strategy to gain control and to
understand what is happening to body and mind [36–39].
Regarding the difference in the TKI decision group, physicians focused more on
the effect and benefit of TKIs, whereas patients were focused more on palliative care.
Physicians may focus more on the effects and benefits of TKIs because they prescribe TKIs
when they believe there is a positive effect and benefit of therapy. We hypothesize that
the physicians’ knowledge of the progression free survival (PFS) benefit shown in patients
treated with TKIs in the randomized controlled trials plays an important role in this result.
This could particularly be the case when patients may not be sufficiently aware of these
results [40,41]. Another explanation for the differences in focus is that patients’ awareness
of having an incurable disease might generate more thoughts regarding their quality of
life and the availability of palliative care. No other studies focused specifically on the
needs and preferences in patients with advanced metastatic DTC. Because DTC is generally
a slowly progressive cancer type, patients with metastatic disease often have long-time
survival while maintaining a good QOL. Therefore, a comparison with other patients with
disseminated malignant tumors could not be used to corroborate our findings, which
highlights the relevance of the present DTC-specific findings.
Our results indicate the importance of talking with patients about their values: values
regarding treatment and decision, and values about daily life were mentioned by both
patients and physicians. Identifying such values is relevant because, in practice, values are
voiced or discussed in a minority of consultations [11], and to talk about values is the most
difficult part of doctor–patient communication. Other studies have showed the importance
of talking about values, e.g., the systematic review of Hyun et al. found that psychosocial
information and supportive care needs may be insufficiently met in DTC survivors [29].
The emotional reaction “I need surgery, there is something in my body that does not belong
there” was also found by Pitt et al. [39]. In other cancers, the importance of the involvement
of family and friends was also found [36–38].
J. Pers. Med. 2021, 11, 682 14 of 17
5. Strengths and Limitations
A strength of our study is that, on the one hand, it contrasts differences and similarities
between two treatment decision-making groups (regarding low-risk and high-risk patients),
and on the other hand, it contrasts differences between the perspectives of physicians and
patients for both decisions. Our study has some limitations. Because of logistic difficulties,
only one focus group interview per treatment decision could be organized. Therefore, our
results may not give an understanding of all of the issues involved [42]. Furthermore,
physicians and patients with DTC in other cultural or geographical settings may have needs
that we did not identify, which could impact generalizability. In general, the results of a
qualitative study cannot be generalized, although the results can be of major importance for
the specialists in the field. This underscores the need for similar cross-cultural validation
studies in other countries.
6. Conclusions
In conclusion, this study illustrates the needs, preferences, and values in patients with
DTC in two different treatment decision groups in both low-risk and high-risk patients.
While many of these are recognized and are overlapping with those of the physicians treat-
ing patients with DTC, some are clearly different and potentially not sufficiently addressed
in daily practice. Communication may be improved by (1) meeting patients’ needs with
respect to stage-specific information provision about the disease and its consequences,
(2) raising awareness among the physicians to inquire about and address patients’ needs
with respect to emotional and psychological support, and (3) addressing patients’ concerns
about palliative care. This may help physicians to improve their communication and better
meet patient needs. The results of this study can also be used to develop decision support
tools to make current doctor–patient communication more SDM-based.
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Appendix A
Table A1. Interview guide.
Initial Questions
Topic Patients Physicians





What is your diagnosis and what kind of treatment
did you receive?
What did the physician tell you about
the diagnosis?
What did the physician tell you about the surgery?
OR
What did the physician tell you about the TKIs?
-
What do you tell patients about
the diagnosis?
What do you tell patients about
the surgery?
OR
What do you tell patients
about TKIs?
Evaluation ImportanceSufficient
What information provided by the physician was
most the important to make a treatment decision?
What aspects of the information provision did you
like or dislike?
What information do you think is
most important for patients?




How should this information be presented?
Would you like to be involved in decision making?
How should this information be
presented?
How do you feel about involving
patients in decision-making during
the consultation?
Values What are important values? What are important valuesfor patients?
Conclusion Do you have any additional remarks? Are there any additional remarks?
Appendix B
Table A2. Picker dimensions.
Picker Dimensions
1. Involvement in decisions and respect for preferences
2. Effective treatment delivered by trusted professionals
3. Continuity of care and smooth transitions
4. Involvement and support for family and carers
5. Clear information, communication and support for self-care
6. Fast access to reliable healthcare advice
7. Emotional support, empathy, and respect
8. Attention to physical and environmental needs
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